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also be treated. On the other hand, perfusing vessels in
nonpulsatile aneurysms are observed for signs of aneurysm
growth. If the etiology of the endoleak is unclear, we find
ourselves in a quandary and undergo a detailed evaluation
of the potential collateral vessels. We may rely on the
expected decrease in aneurysm size to help delineate a
treatment course, or we may perhaps even treat the
endoleak merely to definitively establish the diagnosis. A
nonpalpable aneurysm is treated in a more aggressive fash-
ion than a palpable, nonpulsatile aneurysm. In this situa-
tion, we believe the risks of observation are largely
unknown, and without knowledge of the extent of the
physical forces on the aneurysm wall, the risks of observa-
tion may outweigh the risks of treatment. Quantifications
of these forces are under investigation but have not yet
entered into the clinical arena.6,7 Although some may crit-
icize this protocol as being overly aggressive, we believe
that the overall validity of endovascular repair will depend
on long-term efficacy, which is, at this point, undefined.
Differences between this decision tree and published
regimens include a means to determine the need for
aggressiveness in patients with either undefinable endoleaks
or those caused by perfusing vessels. Fundamental to this
algorithm is that the follow-up physical examinations be
coupled with radiographic evaluation and that a clinician
evaluate the patient both before and after surgery, paying
careful attention to the findings of the physical examina-
tion. Furthermore, this information should be noted in fol-
low-up examination. Because endovascular grafting tech-
niques have lead us down a highly technical path, we are,
in a sense, recommending a step backward to reemphasize
the role and need for the clinical examination.
Roy Greenberg, MD
Department of Vascular Surgery
Cleveland Clinic Foundation
Richard Green, MD
Division of Vascular Surgery
University of Rochester
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Regarding “In situ replacement of infected aortic
grafts with rifampicin-bonded prostheses: the
Leicester experience (1992 to 1998)” 
To the Editors:
In the article by Hayes and colleagues (J Vasc Surg
1999:30:92-8), the authors referred to one of our publica-
tions and erroneously stated that we have suggested that a
polytetrafluoroethylene graft may be used for in situ replace-
ment of infected aortic prostheses.1 The paper that the
authors refer to was addressing whether infected prosthetic
grafts could be preserved successfully, but never suggested
that a new prosthetic graft be used to replace a previously
excised infected prosthetic graft. We have never suggested
this as a option to treat infected prosthetic grafts.2 We believe
that it is extremely important that readers of the article by
Hayes et al do not believe that we are in favor of placing a
new prosthetic graft into an infected field, although the role
of rifampicin-bonded prostheses may prove to be useful.
Keith D. Calligaro, MD
Pennsylvania Hospital
Philadelphia, Pa 
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Reply
We are pleased that Dr Calligaro notes that in situ
replacement with rifampicin-bonded grafts may have a role
to play in the management of graft infection. We accept that
Dr Calligaro and colleagues1 have not previously recom-
mended the replacement of infected prosthetic grafts with a
further prosthetic graft, rather their selective preservation in
extracavitary graft infections. For intracavitary infections,
the focus of our paper, the mainstays of treatment are graft
excision followed by either in situ replacement or extra-
anatomic bypass (EAB). We believe that in situ replacement
overcomes a number of the problems of EAB, namely,
stump blowout, poor flows, lower patency, and prolonged
procedure time. The use of antibiotic-bonded grafts may
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further increase the success of in situ replacement.
Paul D. Hayes, MD
Department of Surgery
Leicester Royal Infirmary
Leicester, United Kingdom
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Regarding “A rational algorithm for duplex scan
surveillance after carotid endarterectomy”
To the Editors:
We read with interest the paper by Roth and col-
leagues regarding requirement for duplex surveillance fol-
lowing carotid endarterectomy.1 We have similarly looked
at this issue and previously published in the Journal of
Vascular Surgery.2 In contrast to Roth and colleagues, we
followed a conservative path with respect to asympto-
matic contralateral carotid artery disease and restenosis.
We only treated patients who developed symptoms in
association with a tight stenosis. We related development
of ipsilateral or contralateral stroke during follow-up to
the presence of contralateral carotid artery disease at the
time of operation, in addition to the development of ipsi-
lateral restenosis or progression of contralateral carotid
artery disease.
We found no relationship between development of
restenosis and ipsilateral stroke. Similarly, there was no
relationship between the presence of tight contralateral
stenosis and subsequent contralateral stroke, nor was
there a relationship between the progression of con-
tralateral artery disease and subsequent contralateral
stroke. On the basis of this, our data would support a
conservative approach to restenosis and contralateral
carotid artery disease. We feel that long-term duplex sur-
veillance following carotid endarterectomy is unwarrant-
ed on these data, and funds would be better spent else-
where.
Jonathan Golledge, MChir
Alun H. Davies, DM
London, United Kingdom
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The vascular surgery section at Charing Cross
Hospital found no benefit from duplex surveillance after
carotid endarterectomy in a prospective study of 305
patients studied at frequent (1 week and 3, 6, 9, 12
months) intervals during the first postoperative year and
annually thereafter. As stated in their letter, “funds would
be better spent elsewhere.” We agree in part with these
conclusions and proposed a “rational” surveillance algo-
rithm based on duplex scanning performed at operation,
at 4 to 6 weeks after endarterectomy, and thereafter on
the basis of carotid disease severity. When enrolled in a
stroke prevention program after carotid endarterectomy,
most patients do not need intensive duplex scan surveil-
lance, if a policy of operation for high-grade internal
carotid artery (ICA) stenosis is adopted. When the intra-
operative duplex scan verifies a normal repair, the inci-
dence of restenosis is low, less than 4% by life table analy-
sis at 3 years. Thus approximately 80% of patients with a
normal repair site and less than 50% contralateral ICA
diameter reduction stenosis can be followed up by clinical
examination and a duplex scan at 1- to 2-year intervals.
Mr Greenhalgh and coauthors similarly noted in their
paper that “restriction of follow-up to patients with >50%
stenosis would have reduced to 78% the percentage of
patients requiring duplex surveillance, and still identifying
8 of 9 patients who required endarterectomy.”
Contralateral >50% ICA stenosis is a lesion with a propen-
sity to progress in severity (approximately 10% incidence
per year) and produce stroke or ICA occlusion. In our
series, approximately 15% of patients with a normal repair
had contralateral >50% stenosis, and duplex surveillance
at 6-month intervals was adequate to detect asympto-
matic disease progression. The carotid repair with resid-
ual or early appearing restenosis is at risk for progression
to a high-grade lesion but occurs in less than 5% of
patients. It seems prudent to me to evaluate these
patients at 6-month intervals by duplex scanning. Duplex
surveillance is one component of an effective stroke pre-
vention program for patients after carotid endarterecto-
my. Control of atherosclerotic risk factors, lipid-lowering
therapy, antiplatelet drug administration, and control of
hypertension are equally important features of the
patient’s surveillance program. In our experience, the risk
of stroke was less than 1% per year in all patient groups, if
the duplex surveillance is tailored to the individual patient
and a policy of repair of high-grade (>75%-80% diameter-
reduction) asymptomatic stenosis is adopted. In their
paper, Mr Greenhalgh and associates did not define what
duplex criteria indicated a high-grade stenosis that war-
ranted consideration for further intervention. At the
University of South Florida, according to our patient sur-
veillance data and correlation studies with contrast arteri-
ography, we recommend repair of a progressive athero-
sclerotic ICA stenosis in appropriately screened surgical
candidates when end-diastolic velocity at the site of steno-
sis is more than 125 cm/s and the ICA:CCA ratio is more
